Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilgamesh raises funds to advance treatments for mental health
The company has also received additional funding from JLS Fund, Gron Ventures, Alumni Ventures, Palo Santo, Satori Capital, Negev Capital, and Route 66. It intends to use the
The company has also received additional funding from JLS Fund, Gron Ventures, Alumni Ventures, Palo Santo, Satori Capital, Negev Capital, and Route 66. It intends to use the
As per the strategic partnership and license agreement terms, Innovent will obtain an exclusive right for developing and commercialising the therapy in China. For the China rights, LG
Spesolimab has been developed to block the interleukin-36 receptor (IL-36R) activation. IL-36R is a signalling pathway in the immune system that is involved in the pathogenesis of many
The latest move follows a definitive agreement signed by the companies on 21 November this year. Merck stated that the tender offer will expire on 10 January next
Nitrase Therapeutics is deploying its NITROME platform for developing several therapies that target nitrases, a new enzymes class discovered by the company. The platform has created leads for
PreHevbrio has been approved for active immunisation against infection which is caused by all known subtypes of HBV in people aged 18 years and above. It is said
The designation will potentially facilitate the development and accelerate new therapies review for treating serious conditions which have unmet medical need. Moleculin noted that the company is now
Hummingbird Bioscience utilises its technologies to drug clinically-validated targets that have earlier been elusive. Its advanced programme, HMBD-001, is a HER3 antibody that targets an epitope on the
Darovasertib is a potential first-in-class protein kinase C (PKC) inhibitor, and crizotinib is an investigational cMET inhibitor. The designation will allow the darovasertib / crizotinib development programme to
With a differentiated mechanism of action, momelotinib has inhibitory ability along three important signalling pathways, Janus kinase (JAK) 1, and JAK2 and activin A receptor type I (ACVR1).